» Articles » PMID: 37256937

PSMC3 Proteasome Subunit Variants Are Associated with Neurodevelopmental Delay and Type I Interferon Production

Abstract

A critical step in preserving protein homeostasis is the recognition, binding, unfolding, and translocation of protein substrates by six AAA-ATPase proteasome subunits (ATPase-associated with various cellular activities) termed PSMC1-6, which are required for degradation of proteins by 26 proteasomes. Here, we identified 15 de novo missense variants in the gene encoding the AAA-ATPase proteasome subunit PSMC3/Rpt5 in 23 unrelated heterozygous patients with an autosomal dominant form of neurodevelopmental delay and intellectual disability. Expression of variants in mouse neuronal cultures led to altered dendrite development, and deletion of the fly ortholog Rpt5 impaired reversal learning capabilities in fruit flies. Structural modeling as well as proteomic and transcriptomic analyses of T cells derived from patients with variants implicated the variants in proteasome dysfunction through disruption of substrate translocation, induction of proteotoxic stress, and alterations in proteins controlling developmental and innate immune programs. The proteostatic perturbations in T cells from patients with variants correlated with a dysregulation in type I interferon (IFN) signaling in these T cells, which could be blocked by inhibition of the intracellular stress sensor protein kinase R (PKR). These results suggest that proteotoxic stress activated PKR in patient-derived T cells, resulting in a type I IFN response. The potential relationship among proteosome dysfunction, type I IFN production, and neurodevelopment suggests new directions in our understanding of pathogenesis in some neurodevelopmental disorders.

Citing Articles

Emerging concepts and treatments in autoinflammatory interferonopathies and monogenic systemic lupus erythematosus.

Goldbach-Mansky R, Alehashemi S, de Jesus A Nat Rev Rheumatol. 2024; 21(1):22-45.

PMID: 39623155 DOI: 10.1038/s41584-024-01184-8.


Construction destruction: Contribution of dyregulated proteostasis to neurodevelopmental disorders.

Winden K, Ruiz J, Sahin M Curr Opin Neurobiol. 2024; 90:102934.

PMID: 39612590 PMC: 11839335. DOI: 10.1016/j.conb.2024.102934.


DDI2 protease controls embryonic development and inflammation via TCF11/NRF1.

Nedomova M, Haberecht-Muller S, Moller S, Venz S, Prochazkova M, Prochazka J iScience. 2024; 27(10):110893.

PMID: 39328932 PMC: 11424978. DOI: 10.1016/j.isci.2024.110893.


Understanding neurodevelopmental proteasomopathies as new rare disease entities: A review of current concepts, molecular biomarkers, and perspectives.

Cuinat S, Bezieau S, Deb W, Mercier S, Vignard V, Isidor B Genes Dis. 2024; 11(6):101130.

PMID: 39220754 PMC: 11364055. DOI: 10.1016/j.gendis.2023.101130.


Exploring the origins of neurodevelopmental proteasomopathies associated with cardiac malformations: are neural crest cells central to certain pathological mechanisms?.

Vignard V, Baruteau A, Toutain B, Mercier S, Isidor B, Redon R Front Cell Dev Biol. 2024; 12:1370905.

PMID: 39071803 PMC: 11272537. DOI: 10.3389/fcell.2024.1370905.


References
1.
Kury S, van Woerden G, Besnard T, Proietti Onori M, Latypova X, Towne M . De Novo Mutations in Protein Kinase Genes CAMK2A and CAMK2B Cause Intellectual Disability. Am J Hum Genet. 2017; 101(5):768-788. PMC: 5673671. DOI: 10.1016/j.ajhg.2017.10.003. View

2.
Schembri L, Dalibart R, Tomasello F, Legembre P, Ichas F, De Giorgi F . The HA tag is cleaved and loses immunoreactivity during apoptosis. Nat Methods. 2007; 4(2):107-8. DOI: 10.1038/nmeth0207-107. View

3.
Ahmed M, Johnson N, Boyd T, Coughlan C, Chial H, Potter H . Innate Immune System Activation and Neuroinflammation in Down Syndrome and Neurodegeneration: Therapeutic Targets or Partners?. Front Aging Neurosci. 2021; 13:718426. PMC: 8481947. DOI: 10.3389/fnagi.2021.718426. View

4.
Akwa Y, Hassett D, Eloranta M, Sandberg K, Masliah E, Powell H . Transgenic expression of IFN-alpha in the central nervous system of mice protects against lethal neurotropic viral infection but induces inflammation and neurodegeneration. J Immunol. 1998; 161(9):5016-26. View

5.
Crow Y, Stetson D . The type I interferonopathies: 10 years on. Nat Rev Immunol. 2021; 22(8):471-483. PMC: 8527296. DOI: 10.1038/s41577-021-00633-9. View